Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples.

Gils, Ann

Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples. [electronic resource] - Inflammatory bowel diseases Apr 2016 - 969-75 p. digital

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

1536-4844

10.1097/MIB.0000000000000709 doi


Adolescent
Adult
Aged
Animals
Antibodies, Monoclonal--immunology
Biological Assay--methods
Biosimilar Pharmaceuticals--therapeutic use
Colitis, Ulcerative--blood
Crohn Disease--blood
Dose-Response Relationship, Immunologic
Enzyme-Linked Immunosorbent Assay--methods
Female
Follow-Up Studies
Gastrointestinal Agents--therapeutic use
Humans
Infliximab--therapeutic use
Male
Mice
Middle Aged
Young Adult